J&J takes Samsung Bioepis to court over claims Korean company breached Stelara biosim settlement
As Stelara biosimilars gradually make their way on to the U.S. market, Johnson & Johnson has accused one early adopter—Samsung Bioepis—of violating the settlement that paved the way for the launch of its biologic copycat earlier this week. The alleged breach of contract has prompted J&J to take the matter to court.
As Stelara biosimilars gradually make their way on to the U.S. market, Johnson & Johnson has accused one early adopter—Samsung Bioepis—of violating the settlement that paved the way for the launch of its biologic copycat earlier this week. The alleged breach of contract has prompted J&J to take the matter to court.
